NCT02411656View on ClinicalTrials.gov

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

June 11, 2015

Primary Completion Date

June 15, 2024

Study Completion Date

December 31, 2028

Conditions
EdemaErythemaEstrogen Receptor NegativeHER2/Neu NegativePeau d'OrangeProgesterone Receptor NegativeRecurrent Inflammatory Breast CarcinomaStage IV Inflammatory Breast CarcinomaTriple-Negative Breast Carcinoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER